Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
October 8, 2007
-
ARCHIVE Paltac and Kobashou to Merge in April 2008
October 8, 2007
-
ARCHIVE New Vision for Medical Device Industry to Call For Fusion of Drugs and Devices
October 8, 2007
-
ARCHIVE Banyu Mounts Sales Drive for Once-Weekly Fosamac
October 8, 2007
-
ARCHIVE GENERICS NEWS IN BRIEF
October 8, 2007
-
ARCHIVE NEW PRODUCTS/GSK, Taisho to Launch Japan's First OTC Drug for Labial Herpes
October 8, 2007
-
ARCHIVE R&D NEWS IN BRIEF
October 8, 2007
-
ARCHIVE DBV Tech. to Enter Japanese Market with Viaskin Technology
October 8, 2007
-
ARCHIVE Korosho Calls on Major Domestic Drug Makers to Develop Vaccines
October 8, 2007
-
ARCHIVE NEW PRODUCTS/Kyowa Hakko Kogyo: Topina Tablets for Partial Seizures
October 8, 2007
-
ARCHIVE Nagoya Lab. to Continue to Operate as a New Company: Pfizer Japan
October 8, 2007
-
ARCHIVE Global Sales of Prevenar to Top US$3 Bil. in 2009: Mr Larsen of Wyeth
October 8, 2007
-
ARCHIVE Roche to Pursue Alliances to Strengthen R&D in 5 Fields
October 8, 2007
-
ARCHIVE Kyorin Pharm. to Merge with Nisshin Kyorin Pharm.
October 8, 2007
-
COLUMN Maurer's Healthcare Insight (89)
October 8, 2007
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 8, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
October 8, 2007
-
ARCHIVE Tanabe Licenses Bepotastine Besilate to ISTA Pharm.
October 8, 2007
-
ARCHIVE JMA Does Not Support NHI Pricing System Proposed by Industry
October 8, 2007
-
ARCHIVE JT, Torii License New Drug for Hyperphosphatemia from Keryx
October 8, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…